BioNTech SE (NASDAQ:BNTX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

BioNTech SE (NASDAQ:BNTX) has received a consensus recommendation of “Moderate Buy” from the eighteen brokerages that are covering the company, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $143.73.

Several research analysts have recently issued reports on BNTX shares. Wells Fargo & Company began coverage on BioNTech in a research report on Wednesday, December 11th. They issued an “overweight” rating and a $170.00 target price for the company. Citigroup assumed coverage on BioNTech in a report on Thursday, March 13th. They issued a “buy” rating and a $145.00 price objective for the company. Truist Financial began coverage on BioNTech in a research report on Friday, January 10th. They set a “buy” rating and a $172.00 price objective for the company. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $171.44 target price on shares of BioNTech in a research report on Tuesday, March 11th. Finally, BMO Capital Markets lifted their price target on shares of BioNTech from $130.00 to $143.00 and gave the company an “outperform” rating in a research report on Tuesday, March 11th.

BioNTech Stock Down 4.1 %

Shares of BioNTech stock opened at $91.06 on Tuesday. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. BioNTech has a 12-month low of $76.53 and a 12-month high of $131.49. The company has a market cap of $21.85 billion, a P/E ratio of -43.36 and a beta of 0.30. The company’s fifty day simple moving average is $110.99 and its two-hundred day simple moving average is $113.65.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings results on Monday, March 10th. The company reported $1.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.70. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.24 billion. During the same quarter in the previous year, the company earned $1.90 earnings per share. BioNTech’s quarterly revenue was down 19.5% on a year-over-year basis. Research analysts anticipate that BioNTech will post -3.88 EPS for the current year.

Hedge Funds Weigh In On BioNTech

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Wealth Enhancement Advisory Services LLC bought a new stake in shares of BioNTech during the 4th quarter valued at $238,000. Probity Advisors Inc. lifted its position in BioNTech by 8.5% during the fourth quarter. Probity Advisors Inc. now owns 1,970 shares of the company’s stock valued at $224,000 after purchasing an additional 154 shares during the last quarter. Jefferies Financial Group Inc. bought a new position in shares of BioNTech in the 4th quarter valued at about $570,000. GF Fund Management CO. LTD. bought a new stake in BioNTech during the fourth quarter worth approximately $235,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in BioNTech by 19.9% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 221,080 shares of the company’s stock worth $25,192,000 after acquiring an additional 36,746 shares during the last quarter. Institutional investors own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.